Replacement hormonal therapy in men: practical aspects


如何引用文章

全文:

详细

参考

  1. Katz A., Burchill C. Androgen therapy: testing before prescribing and monitoring during therapy. Can. Fam. Physician 2007; 53: 1936-1942.
  2. Moncada I. Testosterone and men's quality of life. Aging Male 2006; 9: 189-193.
  3. Bhasin S., Cunningham G. R., Hayes F. J. et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. 2006; 91: 1995-2010.
  4. Travison T. G., Morley J. E., Araujo A. В., et al. The relationship between libido and testosterone levels in aging men. J. Clin. Endocrinol. 2006; 91: 2509-2513.
  5. Morley J. E., Charlton E., Patrick P. et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-1242.
  6. Moore С., Huebler D., Zimmermann Т. et al. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur. Urol. 2004; 46: 80-87.
  7. Wang C., Nieschlag E., Swerdloff R. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur. Urol. 2009; 55: 121-130.
  8. Diver M. J., Imtiaz K. E., Ahmad A. M., et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin. Endocrinol. (Oxford) 2003; 58: 710-717.
  9. de Ronde W., van der Schouw Y. T., Pols H. A. et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin. Chem. 2006; 52: 1777-1784.
  10. Citron J. T., Ettinger В., Rubinoff H. et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J. Urol. (Baltimore) 1996; 155: 529- 533.
  11. Zitzmann M., Faber S., Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. 2006; 91: 4335-4343.
  12. Hajjar R. R., Kaiser F. E., Morley J. E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. 1997; 82: 3793-3796.
  13. Gerstenbluth R. E., Maniam P. N., Corty E. W., Seftel A. D. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J. Androl. 2002; 23: 922-926.
  14. Calof O. M., Singh A. B., Lee M. L., et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Geronto. A. Biol. Sci. Med. Sci. 2005; 60: 1451-1457.
  15. Dipl. Med. Jens Jacobeit Internist/Endokrinologe, Endokrinolodikum. Hamburg.
  16. Bagatell C. J. , Bremner W. J. Androgen and progestagen effects on plasma lipids. Progn. Colardiovasc. Dis. l995; 38: 255-271.
  17. Dobs A. S., Matsumoto A. M., Wang C., Kipnes M. S. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr. Med. Res. Opin. 2004; 20: 729-738.
  18. Stuenkel C. A., Dudley R. E., Yen S. S. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J. Clin. Endocrinol. 1991; 72: 1054-1059.
  19. Wang C., Cunningham G., Dobs A. et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. 2004; 89: 2085-2098.
  20. Kelleher S., Howe C., Conway A. J., Handelsman D. J. Testosterone release rate and duration of action of testosterone pellet implants. Clin. Endocrinol. (Oxford) 2004; 60: 420-428.
  21. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin. Endocrinl. (Oxford) 2006; 65: 275- 28l.
  22. Gooren L. J., Bunck M. C. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861-1891.
  23. Nieschlag E., Buchter D., Von Eckardstein S., et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin. Endocrinol. (Oxford) 1999; 51: 757-763.
  24. Yassin A. A., Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin. Interv. Aging 2007; 2: 577-590.
  25. Shabsigh R., Kaufman J. M., Steidle C., Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. (Baltimore) 2004; 172: 658-663.
  26. Аляев Ю. Г., Винаров А. З., Ахвледиани Н. Д. Выбор лечебной тактики при эректильной дисфункции, ассоциированной с гипогонадизмом. Урология 2010; 4: 37-42.
  27. Yassin A. A., Saad F., Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J. Sex. Med. 2006; 3: 727-735.
  28. Kapoor D., Goodwin E.,, Channer KS, Jones T. H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 2006; 154: 899-906.
  29. English K. M., Steeds R. I., Jones T. H. et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-1911.
  30. Malkin C. J., Pugh P. J., West J. N. et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 2006; 27: 57- 64.
  31. Cherrier M. M., Craft S., Matsumoto A. H. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J. Androl. 2003; 24: 568-576.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011
##common.cookie##